Kun Liu, Zhiwen Tao, Gonghao Li, Mingzhu Li, Jiayu Yin, Lei Zhou
{"title":"炎症负担指数对STEMI患者新发房颤的预测价值。","authors":"Kun Liu, Zhiwen Tao, Gonghao Li, Mingzhu Li, Jiayu Yin, Lei Zhou","doi":"10.3389/fcvm.2025.1599152","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The inflammatory burden index (IBI) is a novel and useful inflammatory marker. However, the association between IBI and new-onset atrial fibrillation (<i>N</i>OAF) in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear. This study focuses on exploring the predictive ability of IBI for NOAF after percutaneous coronary intervention (PCI) in STEMI patients.</p><p><strong>Materials and methods: </strong>This study is a single-center retrospective observational study. Patients diagnosed with STEMI and undergoing primary PCI between October 2022 and February 2025 were continuously enrolled. All enrolled patients received continuous electrocardiogram (ECG) monitoring (>72 h) and were grouped according to whether NOAF occurred during hospitalization. Logistic regression analysis was used to identify potential risk factors for NOAF. Meanwhile, restricted cubic spline (RCS) analysis was employed to thoroughly investigate the possible dose-response relationship between IBI and NOAF.</p><p><strong>Results: </strong>A total of 696 STEMI patients were finally included in this study. The incidence of NOAF during hospitalization was 62/696 (8.9%). After adjusting for potential confounding factors, the results of multivariate logistic regression analysis showed that left ventricular ejection fraction (OR = 0.928, 95% CI: 0.895-0.962), age (OR = 1.048, 95% CI: 1.022-1.075), and IBI (OR = 1.007, 95% CI: 1.003-1.011) were independent factors for NOAF in STEMI patients (<i>P</i> < 0.05). RCS results suggested that there was a non-linear dose-response relationship between IBI and NOAF. After integrating IBI, the ability of the new model to predict NOAF was significantly improved (<i>N</i>RI = 0.617, 95% CI: 0.360-0.873, <i>P</i> < 0.01; IDI = 0.026, 95% CI: 0.007-0.046, <i>P</i> = 0.008).</p><p><strong>Conclusions: </strong>Elevated IBI is an independent risk factor for NOAF after PCI in STEMI patients. Integrating IBI can improve the risk stratification for NOAF in STEMI patients.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1599152"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479414/pdf/","citationCount":"0","resultStr":"{\"title\":\"Predictive value of inflammatory burden index for new-onset atrial fibrillation in STEMI patients.\",\"authors\":\"Kun Liu, Zhiwen Tao, Gonghao Li, Mingzhu Li, Jiayu Yin, Lei Zhou\",\"doi\":\"10.3389/fcvm.2025.1599152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The inflammatory burden index (IBI) is a novel and useful inflammatory marker. However, the association between IBI and new-onset atrial fibrillation (<i>N</i>OAF) in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear. This study focuses on exploring the predictive ability of IBI for NOAF after percutaneous coronary intervention (PCI) in STEMI patients.</p><p><strong>Materials and methods: </strong>This study is a single-center retrospective observational study. Patients diagnosed with STEMI and undergoing primary PCI between October 2022 and February 2025 were continuously enrolled. All enrolled patients received continuous electrocardiogram (ECG) monitoring (>72 h) and were grouped according to whether NOAF occurred during hospitalization. Logistic regression analysis was used to identify potential risk factors for NOAF. Meanwhile, restricted cubic spline (RCS) analysis was employed to thoroughly investigate the possible dose-response relationship between IBI and NOAF.</p><p><strong>Results: </strong>A total of 696 STEMI patients were finally included in this study. The incidence of NOAF during hospitalization was 62/696 (8.9%). After adjusting for potential confounding factors, the results of multivariate logistic regression analysis showed that left ventricular ejection fraction (OR = 0.928, 95% CI: 0.895-0.962), age (OR = 1.048, 95% CI: 1.022-1.075), and IBI (OR = 1.007, 95% CI: 1.003-1.011) were independent factors for NOAF in STEMI patients (<i>P</i> < 0.05). RCS results suggested that there was a non-linear dose-response relationship between IBI and NOAF. After integrating IBI, the ability of the new model to predict NOAF was significantly improved (<i>N</i>RI = 0.617, 95% CI: 0.360-0.873, <i>P</i> < 0.01; IDI = 0.026, 95% CI: 0.007-0.046, <i>P</i> = 0.008).</p><p><strong>Conclusions: </strong>Elevated IBI is an independent risk factor for NOAF after PCI in STEMI patients. Integrating IBI can improve the risk stratification for NOAF in STEMI patients.</p>\",\"PeriodicalId\":12414,\"journal\":{\"name\":\"Frontiers in Cardiovascular Medicine\",\"volume\":\"12 \",\"pages\":\"1599152\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479414/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Cardiovascular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fcvm.2025.1599152\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1599152","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Predictive value of inflammatory burden index for new-onset atrial fibrillation in STEMI patients.
Background: The inflammatory burden index (IBI) is a novel and useful inflammatory marker. However, the association between IBI and new-onset atrial fibrillation (NOAF) in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear. This study focuses on exploring the predictive ability of IBI for NOAF after percutaneous coronary intervention (PCI) in STEMI patients.
Materials and methods: This study is a single-center retrospective observational study. Patients diagnosed with STEMI and undergoing primary PCI between October 2022 and February 2025 were continuously enrolled. All enrolled patients received continuous electrocardiogram (ECG) monitoring (>72 h) and were grouped according to whether NOAF occurred during hospitalization. Logistic regression analysis was used to identify potential risk factors for NOAF. Meanwhile, restricted cubic spline (RCS) analysis was employed to thoroughly investigate the possible dose-response relationship between IBI and NOAF.
Results: A total of 696 STEMI patients were finally included in this study. The incidence of NOAF during hospitalization was 62/696 (8.9%). After adjusting for potential confounding factors, the results of multivariate logistic regression analysis showed that left ventricular ejection fraction (OR = 0.928, 95% CI: 0.895-0.962), age (OR = 1.048, 95% CI: 1.022-1.075), and IBI (OR = 1.007, 95% CI: 1.003-1.011) were independent factors for NOAF in STEMI patients (P < 0.05). RCS results suggested that there was a non-linear dose-response relationship between IBI and NOAF. After integrating IBI, the ability of the new model to predict NOAF was significantly improved (NRI = 0.617, 95% CI: 0.360-0.873, P < 0.01; IDI = 0.026, 95% CI: 0.007-0.046, P = 0.008).
Conclusions: Elevated IBI is an independent risk factor for NOAF after PCI in STEMI patients. Integrating IBI can improve the risk stratification for NOAF in STEMI patients.
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.